
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Paul Johnson is scientist at Pfizer Global Research and Development Global Biologics, Bioprocess R&D
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Published: October 2nd 2009 | Updated:
Published: March 2nd 2009 | Updated: